Author:
Gong Liping,Sun Xifeng,Jia Ming
Abstract
AbstractThe immune microenvironment of osteosarcoma (OS) has been reported to play an important role in disease progression and prognosis. However, owing to tumor heterogeneity, it is not ideal to predict OS prognosis by examining only infiltrating immune cells. This work aimed to build a prognostic gene signature based on similarities in the immune microenvironments of OS patients. Public datasets were used to examine the correlated genes, and the most consistent dominant infiltrating immune cell type was identified. The LASSO Cox regression model was used to establish a multiple-gene risk prediction signature. A nine-gene prognostic signature was generated from the correlated genes for M0 macrophages and then proven to be effective and reliable in validation cohorts. Signature comparison indicated the priority of the signature. Multivariate Cox regression models indicated that the signature risk score is an independent prognostic factor for OS patients regardless of the Huvos grade in all datasets. In addition, the results of the association between the signature risk score and chemotherapy sensitivity also showed that there was no significant difference in the sensitivity of any drugs between the low- and high-risk groups. A GSEA of GO and KEGG pathways found that antigen processing- and presentation-related biological functions and olfactory transduction receptor signaling pathways have important roles in signature functioning. Our findings showed that M0 macrophages were the dominant infiltrating immune cell type in OS and that the new gene signature is a promising prognostic model for OS patients.
Funder
Scientific and Technological Innovation Program for Clinical Medicine of Jinan
Cultivation Fund Program of the Second Hospital of Shandong University
Publisher
Springer Science and Business Media LLC
Reference98 articles.
1. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).
2. Miller, K. D. et al. Cancer statistics for adolescents and young adults, 2020. CA Cancer J. Clin. 70, 443–459 (2020).
3. Daw, N. C. et al. Recurrent osteosarcoma with a single pulmonary metastasis: A multi-institutional review. Br. J. Cancer 112, 278–282 (2015).
4. Lewis, I. J. et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European osteosarcoma intergroup. J. Natl. Cancer Inst. 99, 112–128 (2007).
5. Lahr, C. A. et al. A humanised rat model of osteosarcoma reveals ultrastructural differences between bone and mineralised tumour tissue. Bone 158, 116018 (2022).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献